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Background
Bipolar disorder is a relatively common, long term and
disabling psychiatric illness that is associated with high
levels of functional impairment, morbidity, mortality and
an increased risk of suicide [1]. The aim of the present
study was to evaluate the functional status of Greek
patients with acute mania in the context of bipolar disor-
der, after 12 weeks of pharmacological intervention.
Materials and methods
EMBLEM (European Mania in Bipolar Evaluation of Med-
ication) is a 24 month prospective observational study for
in- and outpatients with acute mania. The functional sta-
tus of the Greek population was studied during the acute
phase of the illness (first 12 weeks), as reported by
changes in their relationship status, work, social activities
and life satisfaction. Changes in alcohol, cannabis and
other substance use are also reported.
Results
A total of 3684 patients were enrolled in 14 European
countries and the Greek population consisted of 645 indi-
viduals (18%). At baseline, 18 % of the Greek population
were inpatients compared to only 4% by week 12. Work
impairment was mild or not present for 38% of the Greek
population by week 12 compared to 27% at baseline. Sat-
isfaction with life increased from baseline to the 12-week
endpoint (52% of the Greek patients were satisfied or very
satisfied compared to 32% on baseline). The percentage
of alcohol, cannabis and other substance use decreased
from baseline to week 12.
Conclusions
In this large naturalistic study, improvement of functional
status was observed in the Greek population, especially
with respect to the domains of work and life satisfaction.
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